Dyadic International, Inc. (DYAI) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St set to slip as US-Iran tensions cloud start to second half
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil falls as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
November 10, 2022 4:00 PM ESTReceived regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidatePresented safety, efficacy, and productivity data at World Vaccine Congress EuropeNew and expanded collaborations with top animal health companies to develop... More
